The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

• Status: Unknown status
• Trial end date: 2021-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The study group received antipsychotic drugs combined with Computerized Cognitive Remediation Therapy (CCRT) for 4 times/week for 45 minutes each time. The control group only received antipsychotic drugs. For a total of 12 weeks. Brain Derived Neurotrophic Factor (BDNF) and Tropomyosin-related kinase B (Trk B) genes in peripheral blood were detected in both groups before and after treatment. Clinical symptoms and executive function assessment were performed in both groups before and after treatment. The relevance of genes and their effects on downstream protein expression levels led to a molecular genetic mechanism for the efficacy of Computerized Cognitive Remediation Therapy (CCRT) .

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Mental Health Center
• Treatments: Antipsychotic Agents; Clozapine

Criteria

Inclusion Criteria:

1. Age 18-45 years old, Han nationality, male or female;

2. Comply with the American Diagnostic Criteria for Mental Disorder (DSM-V) diagnostic criteria for "schizophrenia";

3. The course of the disease and continued treatment with antipsychotic drugs for > 2 years, stable for at least one month;

4. Positive NegativeSyndrome Scale (PANSS) < 70 points;

5. intelligence quotient (IQ)>80;

6. Cultural, social and educational backgrounds are sufficient to understand informed consent and research content.

Exclusion Criteria:

1. Concomitant diagnosis in addition to Diagnostic and Statistical Manual of Mental Disorders-V other than schizophrenia;

2. Central nervous system organic diseases;

3. There are alcohol or other substances dependent or abused in the past two months, causing significant social and cognitive impairment;

4. In the past year, there have been major life events such as widowhood;

5. Those who have serious suicide attempts (the third item of the (Hamilton Depression Scale-17,HAMD-17) scale "suicide" ≥ 3 points);

6. The current patient's severe unstable physical disease;

7. pregnant women and lactating women;

8. Those who have received modified electroconvulsive therapy (MECT) and repetitive Transcranial Magnetic Stimulation (rTMS) treatment in the past month;

9. Those who have been ineffective for more than 3 months of systemic psychotherapy.